Skip to main content

SABCS 2021

News and expert insight from the 2021 San Antonio Breast Cancer Symposium
SABCS 2021 research news

PADA-1 shows clinical utility of blood ESR1 mutation monitoring

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

Research news from SABCS 2021

14-12-2021 | SABCS 2021 | Conference coverage | News

Anthracycline addition to taxane supported for early breast cancer

A patient-level meta-analysis has demonstrated a significant reduction in the risk for invasive recurrence with the use of an anthracycline alongside taxane-based chemotherapy for the treatment of early-stage breast cancer.

10-12-2021 | SABCS 2021 | Conference coverage | News

ctDNA target mutations show prognostic value in advanced breast cancer

Circulating tumor DNA target mutations may represent a promising prognostic biomarker among women receiving first-line ribociclib plus letrozole for hormone receptor-positive, HER2-negative advanced breast cancer, research suggests.

10-12-2021 | SABCS 2021 | Conference coverage | News

Dual checkpoint inhibition shows promise for highly mutated HER2-negative MBC

Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for people with HER2-negative metastatic breast cancer and high tumor mutational burden, phase 2 NIMBUS study data show.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Medicine Matters conference coverage is brought to you in partnership with medwireNews